دورية أكاديمية
Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses.
| العنوان: | Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses. |
|---|---|
| المؤلفون: | Cetto GL; Division of Medical Oncology, University of Verona, Italy., Franceschi T, Turrina G, Chiarion-Sileni V, Capelli MC, Bellini A, Paccagnella A, Bassetto MA, Molino AM, de Sandre G |
| المصدر: | Seminars in surgical oncology [Semin Surg Oncol] 1988; Vol. 4 (3), pp. 184-90. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8503713 Publication Model: Print Cited Medium: Print ISSN: 8756-0437 (Print) Linking ISSN: 10982388 NLM ISO Abbreviation: Semin Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, NY : Wiley-Liss Original Publication: New York : Liss, c1985- |
| مواضيع طبية MeSH: | Kidney Neoplasms*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Renal Cell/*secondary , Interferon Type I/*administration & dosage , Interferon-alpha/*administration & dosage , Vinblastine/*administration & dosage, Adult ; Aged ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/therapy ; Drug Administration Schedule ; Drug Evaluation ; Female ; Humans ; Interferon alpha-2 ; Interferon-alpha/adverse effects ; Male ; Middle Aged ; Recombinant Proteins ; Vinblastine/adverse effects |
| مستخلص: | Twenty-six patients with metastatic renal cell carcinoma (RCC) were treated in a phase I-II trial with recombinant interferon alpha-2b (alpha-IFN) and vinblastine (VBL) in combination. Patients received IFN at a starting dose of 3 x 10(6) IU/m2 subcutaneously three times a week and VBL 0.1 mg/kg intravenously every 3 weeks, with dose modification for toxicity. All patients were evaluable for toxicity; 18 patients were evaluable for efficacy. An objective response rate of 44% was observed (eight of 18 patients, with one complete response and seven partial responses). The median duration of response was 5 months. The actuarial survival of responding patients was significantly longer than that of nonresponding patients. In general, the toxicity was tolerable; the subjective toxicity and fever were similar to that reported for the same doses of IFN alone. Only a mild neurotoxicity, usually mixed polyneuropathy, occurred with increased frequency. Alpha-IFN and VBL administered at low doses in combination demonstrated the highest response rate so far reported in RCC without significant toxicity. |
| Number of References: | 19 |
| المشرفين على المادة: | 0 (Interferon Type I) 0 (Interferon alpha-2) 0 (Interferon-alpha) 0 (Recombinant Proteins) 5V9KLZ54CY (Vinblastine) |
| تواريخ الأحداث: | Date Created: 19880101 Date Completed: 19881219 Latest Revision: 20191029 |
| رمز التحديث: | 20221208 |
| DOI: | 10.1002/ssu.2980040309 |
| PMID: | 3055162 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 8756-0437 |
|---|---|
| DOI: | 10.1002/ssu.2980040309 |